{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-26-007158","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2026-05-13T20:22:27+00:00","discovered_at":"2026-05-13T20:23:31.389750+00:00","generated_at":"2026-05-13T21:48:09.748055+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M","bullets":["Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.","Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025.","Patient hub enrollment reached ~400 patients; 25% from community settings.","Cash, equivalents, and investments totaled $56.7M as of March 31, 2026.","Permanent J-code (J3404) assigned effective April 1, 2026, expected to streamline access."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-007158","json":"https://secwatch.observer/filing/0000950103-26-007158.json","markdown":"https://secwatch.observer/filing/0000950103-26-007158.md","text":"https://secwatch.observer/filing/0000950103-26-007158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/0000950103-26-007158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/dp246650_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T21:48:09.748055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}